Comments
Natco Pharma Ltd has on Friday announced that its marketing partner, Breckenridge Pharmaceutical Inc., has received final approval for its Abbreviated New Drug Application (ANDA) for Pomalidomide Capsules, from the U.S. Food and Drug Administration {USFDA).
Also, Hyderabad-based Natco and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the U.S. district court for this product.
Celgene, sells Pomalidomide Capsules under Brand name Pomalyst in the US market, which is indicated for the treatment of patients who have multiple myeloma cancer.
As per industry sales data, Pomalyst had annual sales of $957 million during the twelve months ending September 2020, according to a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.